Moderna, Inc. (MRNA)
What changed in recent filings
- Europe segment 18% → 3%Dec 31, 2024 → Dec 31, 2025
- Institutions — 1 new · 2 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Moderna, Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 2 → 2026 Q2: 3 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Moderna, Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Co1.16% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associatesunder 0.01% of portfolio · since 2025 Q3
- Capital World Investors0.18% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Moderna. A developer of mRNA-based vaccines and treatments. After its COVID-19 vaccine, it is developing varied pipelines in flu, cancer, and more.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Moderna, Inc. is classified under the Biotech & Health sector. See peers below.
Moderna, Inc. key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Moderna, Inc. vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
MRNA segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Moderna, Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
MRNA on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
MRNA FAQ
What is Moderna, Inc. (MRNA)?
Moderna. A developer of mRNA-based vaccines and treatments. After its COVID-19 vaccine, it is developing varied pipelines in flu, cancer, and more.
What sector is Moderna, Inc. in?
Moderna, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Moderna, Inc.'s key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) -27.6%, Operating margin -562.1%, Net margin -141.4%, ROE -32.6%, Debt-to-equity 0.09x. Definitions and interpretation are available on Stocklore.
Where can I analyze Moderna, Inc. (MRNA) stock?
On Stocklore you can see MRNA's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.